Marex Group (MRX) CFO sells 3,700 shares in open market

Rhea-AI Filing Summary

Marex Group Ltd (MRX) director and Chief Financial Officer Rob Irvin reported selling a total of 3,700 Ordinary Shares on August 14, 2026 in open-market transactions. The sales comprised 3,500 shares at a weighted average price of $70.91 (individual trades ranged from $70.69 to $71.35) and 200 shares at a weighted average price of $71.87 (ranging from $71.71 to $72.02). A footnote states that the ordinary shares reported for Irvin include 25,300 shares underlying deferred bonus plan awards, each representing a contingent right to receive one ordinary share upon vesting and settlement.

Insider Trade Summary

Net Seller: 3,700 shares

Net Sell 2 txns

Insider Irvin Rob

Role Chief Financial Officer

Sold 3,700 shs ($263K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1, F3	3,500	$70.9064	$248K
Sale	Ordinary Shares F2, F3	200	$71.865	$14K

Holdings After Transaction: Ordinary Shares — 31,046 shares (Direct)

Footnotes (3)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $70.69 to $71.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $71.71 to $72.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The number of ordinary shares reported herein includes 25,300 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

Key Figures

Total shares sold: 3,700 shares Weighted average price (3,500 shares): $70.9064 per share Weighted average price (200 shares): $71.8650 per share +3 more

6 metrics

Total shares sold 3,700 shares Ordinary Shares sold by CFO Rob Irvin on 2026-08-14

Weighted average price (3,500 shares) $70.9064 per share Sale of 3,500 Ordinary Shares; trades from $70.69 to $71.35

Weighted average price (200 shares) $71.8650 per share Sale of 200 Ordinary Shares; trades from $71.71 to $72.02

Deferred bonus plan awards 25,300 shares Ordinary shares underlying deferred bonus plan awards reported for Rob Irvin

Price range first block $70.69–$71.35 Range of individual trade prices within the 3,500-share sale

Price range second block $71.71–$72.02 Range of individual trade prices within the 200-share sale

Key Terms

weighted average price, deferred bonus plan awards, contingent right

3 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

deferred bonus plan awards financial

"includes 25,300 shares underlying deferred bonus plan awards previously granted"

Deferred bonus plan awards are payments promised to employees or executives that are earned now but paid out later, often only if certain performance goals are met or the employee remains with the company. For investors, they matter because they influence management’s incentives and company expenses over time—like a delayed paycheck that encourages someone to stay and meet targets—and can affect future cash needs, reported compensation costs, and potential share dilution.

contingent right financial

"Each award represents a contingent right to receive one (1) ordinary share"

FAQ

What insider transaction did MRX report for CFO Rob Irvin on August 14, 2026?

Marex Group Ltd (MRX) reported that CFO Rob Irvin sold 3,700 Ordinary Shares on August 14, 2026 in open-market transactions at weighted average prices around $71 per share, according to the Form 4 filing.

How many Marex Group Ltd (MRX) shares did Rob Irvin sell and at what prices?

Rob Irvin sold 3,500 shares at a weighted average price of $70.91 and 200 shares at a weighted average price of $71.87, with individual trades ranging roughly between $70.69 and $72.02.

Were Rob Irvin’s MRX share sales made under a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not marked, and the footnotes do not reference any trading plan, so the reported sales are not identified as being made under a Rule 10b5-1 plan.

What does the Form 4 say about Rob Irvin’s deferred bonus awards in MRX shares?

A footnote explains that Irvin’s reported ordinary shares include 25,300 shares underlying deferred bonus plan awards, each award being a contingent right to receive one Marex ordinary share upon vesting and settlement.

What price ranges applied to Rob Irvin’s MRX share sales on August 14, 2026?

For the 3,500-share block, trades occurred between $70.69 and $71.35. For the 200-share block, trades ranged from $71.71 to $72.02. Reported prices are weighted averages within those ranges.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/18/2026 - 04:05 PM Accepted by SEC EDGAR 08/18/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Irvin Rob

(Last) (First) (Middle)

C/O MAREX GROUP LIMITED, 155 BISHOPSGATE

(Street)

LONDON UNITED KINGDOM EC2M 3TQ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Marex Group Ltd [ MRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/14/2026		S		3,500	D	$70.9064(1)	31,246(3)	D
Ordinary Shares	08/14/2026		S		200	D	$71.865(2)	31,046(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $70.69 to $71.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. The price reported in Column 4 is a weighted average price. These shares were sold in transactions at prices ranging from $71.71 to $72.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The number of ordinary shares reported herein includes 25,300 shares underlying deferred bonus plan awards previously granted to the Reporting Person. Each award represents a contingent right to receive one (1) ordinary share of the Issuer upon vesting and settlement of the applicable award.

	/s/ Scott Linsley as Attorney-in-Fact, for Rob Irvin	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)